HHS: FDA review not needed for coronavirus LDTs

By Brian Casey, LabPulse.com editorial director

August 20, 2020 -- Laboratory-developed tests (LDTs) to diagnose whether patients are infected with the SARS-CoV-2 virus will not have to undergo review by the U.S. Food and Drug Administration (FDA), according to an August 19 guidance by the U.S. Department of Health and Human Services (HHS).

In the guidance, the HHS said that the FDA will not require labs to go through premarket review of LDTs for COVID-19 before they can be used on patients. Labs can choose to seek emergency use authorization (EUA) from the FDA if they wish, and the agency will adjudicate these submissions.

Labs that wish to use LDTs must do so understanding that these tests will not be eligible for coverage under the Public Readiness and Emergency Preparedness (PREP) Act, which gives the federal government new authority in the wake of the public health emergency caused by the COVID-19 outbreak. LDTs are also subject to regulation by the U.S. Centers for Medicare and Medicaid Services under CLIA.

Labs that have an EUA to detect SARS-CoV-2 or its antibodies are unaffected by the announcement, according to a statement on the HHS website.

The agency's move was lauded by lab industry observers, including the American Association for Clinical Chemistry (AACC), which noted that the directors of clinical laboratories already meet stringent regulatory requirements under CLIA, according to David Grenache, president of AACC.

Grenache noted that CLIA-regulated labs performed some of the first COVID-19 tests when the pandemic began, before the FDA-approved tests became available.

"Unlike commercial test kits sold by manufacturers to various healthcare entities, laboratory-developed tests are used only by the lab that created them," Grenache noted in a statement. "AACC looks forward to continuing to work with HHS, FDA, and this administration to ensure that patients receive accurate, timely testing unhindered by duplicative federal regulation."

FDA clears EUA change for Applied DNA coronavirus test
Applied DNA Sciences announced that the U.S. Food and Drug Administration (FDA) has granted an emergency use authorization (EUA) amendment for its Linea...
FDA spurs development of COVID-19 tests for use outside labs
The U.S. Food and Drug Administration (FDA) has published a template to help commercial companies develop COVID-19 molecular diagnostic and antigen tests...
FDA grants first coronavirus clearance for sample pooling to Quest
The U.S. Food and Drug Administration has granted Quest Diagnostics the first emergency use authorization for a SARS-CoV-2 molecular diagnostic for testing...
AMP survey shows labs' struggles with COVID-19 supply shortages
A survey conducted by the Association for Molecular Pathology (AMP) illustrates the challenges clinical labs have faced in securing supplies for COVID-19...
FDA policy change may put an end to 'Wild West' of coronavirus antibody tests
The U.S. Food and Drug Administration (FDA) is cracking down on requirements for commercial manufacturers of antibody tests for the novel coronavirus,...

Copyright © 2020 LabPulse.com

Last Updated ls 8/20/2020 2:30:05 PM



Register below for our weekly Letter from the Editor to receive the latest Clinical Lab news and insights.
Email
Subscribe Today
Do you want to be a Microbiology Insider?

When LabPulse gets hot new information, our Insiders are the first to find out. Stay current in today's competitive market by receiving our exclusive free email updates.

Yes, Keep Me Current